[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613889":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":36,"responsibleParty":54,"collaborators":25,"id":56,"slug":25,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Mount Sinai Hospital, Canada","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Time-restricted eating","EXPERIMENTAL","Time-restricted eating protocol consisting of time-restricted eating with 18 hours of fasting and 6 hour window of eating (between 2 to 8 PM) every day.",[13],"Behavioral: Time-restricted eating",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard lifestyle","ACTIVE_COMPARATOR","Standard lifestyle recommendation as per Diabetes Canada Guidelines.",[19],"Behavioral: Standard lifestyle",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"BEHAVIORAL","18 hours of fasting and 6 hour window of eating (between 2 to 8 PM) every day for 52 weeks.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"standard lifestyle recommendations as per Diabetes Canada guidelines \\[where patients are encouraged to maintain regularity in timing and spacing of meals with no specific recommendation regarding hours of fasting\\]",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Caroline K Kramer, MD, PhD","CONTACT","+1-416-586-4800","7628","Caroline.Kramer@sinaihealth.ca",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Leadership Sinai Centre for Diabetes","RECRUITING","Toronto","Ontario","M5T3L9","Canada",{"type":45,"coordinates":46},"Point",[47,48],-79.39864,43.70643,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":34,"email":35},"Kramer","+1416-586-4800",{"type":55,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100613889",false,"NCT07272460","Time Restricted-EAting for Type 2 Diabetes and MEtabolic Health: the TEA TIME Trial","Time Restricted-eating and Metabolic Health in Patients With Type 2 Diabetes","TEA-TIME","Inclusion Criteria:\n\n* Individuals with previously diagnosed BMI ≥ 25 kg\u002Fm2 and type 2 diabetes within preceding 10 years.\n* Age 18 - 75 years inclusive\n* Stable weight over past 12 weeks (less than 5% change in body weight) (self-reported)\n* Diabetes treatment consisting of lifestyle only or metformin, dipeptidyl peptidase-4 (DPP-4) inhibitor, and sodium-glucose co-transporter 2 (SGLT2) inhibitors either as monotherapy or in combination.\n* Ability to read and understand English\n\nExclusion Criteria:\n\n* Current diabetes treatment with insulin, glucagon-like peptide-1 receptor agonists, and\u002For sulfonylureas.\n* Use of any other pharmacological treatment for weight-loss\n* Previous surgical treatment for weight loss such as gastric bypass or gastric band\n* Any history of eating disorder\n* Currently pregnant or lactating\n* Renal dysfunction as evidenced by estimated glomerular filtration rate \\\u003C 25 ml\u002Fmin by CKD-EPI Creatinine Equation\n* New York Heart Association class II-IV heart failure\n* Hepatic disease considered to be clinically significant (includes jaundice, chronic hepatitis, or previous liver transplant) or transaminases \\>2.5X the upper limit of normal\n* Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer)\n* Any other factor likely to limit adherence to the study, in the opinion of the investigators\n* Concurrent participation in another research study relevant to diabetes and metabolic health","ALL","18 Years","75 Years",{"count":67,"type":68},112,"ESTIMATED","INTERVENTIONAL",[71],"NA","Time-restricted eating - where no food is consumed over a period of time - has been shown to promote weight loss and improve cardio-metabolic function. In individuals with type 2 diabetes, it is also been shown to improve glucose control. The investigators propose a randomized controlled trial to determine whether time-restricted eating is an effective therapeutic strategy that can preserve pancreatic beta-cell function and improve glycemic control early in participants with type 2 diabetes.",[74,75],"Type 2 Diabetes","Overweight (BMI > 25)",[77,9,78,79],"Randomized controlled trial","Intermittent fasting","Type 2 diabetes","2026-02-09",{"date":82,"type":83},"2026-02-11","ACTUAL",{"date":85,"type":83},"2026-02-01",{"date":87,"type":68},"2029-07-31",{"name":5,"class":6},1]